ChiCTR2600116691 版本V1.0 版本创建时间2026/01/14 08:21:05 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600116691 

最近更新日期:

Date of Last Refreshed on:

2026-01-14 08:17:24 

注册时间:

Date of Registration:

2026-01-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

经颅双平面波超声融合人工智能技术在脑出血和帕金森诊断中的探索性研究

Public title:

Transcranial Dual-Plane-Wave Ultrasound Combined with Artificial Intelligence for the Diagnosis of Intracerebral Hemorrhage and Parkinson‘s Disease: An Exploratory Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

经颅双平面波超声融合人工智能技术在脑出血和帕金森诊断中的探索性研究

Scientific title:

Transcranial Dual-Plane-Wave Ultrasound Combined with Artificial Intelligence for the Diagnosis of Intracerebral Hemorrhage and Parkinson‘s Disease: An Exploratory Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李一鸣 

研究负责人:

丁红, 李一鸣 

Applicant:

Li Yiming 

Study leader:

Ding Hong, Li Yiming 

申请注册联系人电话:

Applicant telephone:

+86 188 1820 8991

研究负责人电话:

Study leader's telephone:

+86 136 5188 6013

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yiyi-vicki@163.com

研究负责人电子邮件:

Study leader's E-mail:

ding_hong@fudan.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市乌鲁木齐中路12号

研究负责人通讯地址:

上海市乌鲁木齐中路12号

Applicant address:

No. 12, Middle Urumqi Road, Shanghai

Study leader's address:

No. 12, Middle Urumqi Road, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属华山医院

Applicant's institution:

Huashan Hospital affiliated to Fudan University

研究负责人所在单位:

复旦大学附属华山医院

Affiliation of the Leader:

Huashan Hospital affiliated to Fudan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2025)临审第(1567)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属华山医院伦理审查委员会

Name of the ethic committee:

Ethics Review Committee of Huashan Hospital Affiliated to Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-12-23 00:00:00

伦理委员会联系人:

戚玮琳

Contact Name of the ethic committee:

Qi Weilin

伦理委员会联系地址:

上海市乌鲁木齐中路12号

Contact Address of the ethic committee:

No. 12, Middle Urumqi Road, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 5288 8045

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属华山医院

Primary sponsor:

Huashan Hospital affiliated to Fudan University

研究实施负责(组长)单位地址:

上海市乌鲁木齐中路12号

Primary sponsor's address:

No. 12, Middle Urumqi Road, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院

具体地址:

上海市乌鲁木齐中路12号

Institution
hospital:

Huashan Hospital affiliated to Fudan University

Address:

No. 12, Middle Urumqi Road, Shanghai

经费或物资来源:

自筹

Source(s) of funding:

Self support

Target disease:

Cerebral hemorrhage; Parkinson's Disease

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

研究使用双平面波超声诊断脑出血及帕金森的价值  

Objectives of Study:

To study the value of using double plane wave ultrasound in the diagnosis of cerebral hemorrhage and Parkinson's disease

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 脑出血第一部分队列:年龄18岁以上;头颅CT确诊的脑实质出血(自发性或创伤性);发病时间在6小时以内;我院收治入ICU病房;颞窗透声良好(可显示对侧颅骨及中线结构);患者或家属签署知情同意书。 2. 脑出血第二部分队列:年龄18岁以上;经头颅CT确诊的自发性脑出血;入院时间在2小时以内;颞窗透声良好;患者或家属签署知情同意书。 3. 帕金森队列:选择首诊入院的PD患者;年龄在60岁以上;患者接受国际运动障碍学会修订版帕金森病评定量表(MDS-UPDRS量表)评分;已签署知情同意书。

Inclusion criteria

1. Cerebral hemorrhage Part I cohort: Age > 18 years; Parenchymal hemorrhage (spontaneous or traumatic) confirmed by head CT; The onset time was within 6 hours; Patients were admitted to the ICU ward of our hospital. The temporal window had good sound transmission (the contralateral skull and midline structures could be shown). Patients or their families provided written informed consent. 2. Cerebral hemorrhage part 2 cohort: age above 18 years old; Spontaneous intracerebral hemorrhage confirmed by head CT; The admission time was within 2 hours; The temporal window had good sound transmission. Patients or their families provided written informed consent. 3. Parkinson's cohort: PD patients who were first admitted to the hospital were selected; Be over 60 years of age; Patients were assessed by the Movement Disorders Society Revised Parkinson's Disease Rating Scale (MDS-UPDRS). Written informed consent was obtained.

排除标准:

1. 脑出血第一部分队列:已行开颅血肿清除手术;妊娠期妇女;颞部存在手术伤口或敷料包扎影响探头放置者;预期入院24小时死亡的严重病例。 2. 脑出血第二部分队列:入院时已具备急诊手术指征。 3. 帕金森队列:合并精神疾病、脑血管病、痴呆等严重的中枢神经系统疾病者;合并原发性震颤等其他具有帕金森样症状疾病者;合并帕金森叠加综合征者;颅脑外伤及手术史者;颅脑 CT 或 MRI 检查发现颅内明确病灶并有相应神经系统症状的患者;一氧化碳及其他化学药物、药品中毒病史;多系统萎缩、进行性核上性麻痹等其他神经系统变性疾病者。

Exclusion criteria:

1. Cerebral hemorrhage Part I cohort: Craniotomy for hematoma evacuation has been performed. A pregnant woman; The presence of surgical wound or dressing in the temporal region affected the placement of the probe. Severe cases expected to die within 24 hours of admission. 2. Cerebral hemorrhage part II cohort: emergency surgery was indicated at admission.

研究实施时间:

Study execute time:

From 2026-01-12 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-20 00:00:00 To 2027-12-31 00:00:00  

干预措施:

Interventions:

组别:

脑出血第一部分

样本量:

60

Group:

Cerebral hemorrhage part I

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

脑出血第二部分

样本量:

50

Group:

Cerebral hemorrhage part II

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

帕金森

样本量:

156

Group:

Parkinson's Disease

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

复旦大学附属华山医院 

单位级别:

三甲 

Institution
hospital:

Huashan Hospital affiliated to Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血肿大小

指标类型:

主要指标

Outcome:

Hematoma size

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑中线

指标类型:

主要指标

Outcome:

Midline of brain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑室出血

指标类型:

次要指标

Outcome:

Intraventricular hemorrhage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

黑质面积

指标类型:

主要指标

Outcome:

Substantia nigra area

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

第三脑室宽度

指标类型:

次要指标

Outcome:

Width of the third ventricle

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血肿体积

指标类型:

次要指标

Outcome:

Hematoma volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑干周围脑池受压情况

指标类型:

次要指标

Outcome:

Compression of peribrainstem cisterns

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑血流相关参数

指标类型:

次要指标

Outcome:

Cerebral blood flow parameters

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

黑质/中脑面积

指标类型:

次要指标

Outcome:

Substantia nigra/midbrain area

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

MDS-UPDRS量表评分

指标类型:

次要指标

Outcome:

MDS-UPDRS scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-01-14 08:17:24